MA242

MA242 is a **synthetic small molecule** designed as a **dual inhibitor of MDM2 and NFAT1** for the treatment of cancer, particularly targeting pancreatic cancer, hepatocellular carcinoma (HCC), and breast cancer. MA242 binds to the C-terminal RING domain of the MDM2 protein, promoting MDM2 auto-ubiquitination and proteasomal degradation, and enhances degradation of NFAT1, ultimately repressing MDM2 transcription. This results in growth inhibition, cell cycle arrest, and apoptosis of cancer cells, regardless of p53 status. MA242 demonstrates high selectivity and potency against tumor cells with minimal cytotoxicity in normal cells. Preclinical models show efficacy both alone and in combination with standard chemotherapy (e.g., gemcitabine). MA242 is based on the structure of makaluvamine, a marine sponge-derived compound, but has been synthetically optimized for dual target activity[1][3][4].